These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 14585914)
1. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Moride Y; Ducruet T; Rochon S; Lavoie F Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914 [TBL] [Abstract][Full Text] [Related]
2. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Zhao SZ; Wentworth C; Burke TA; Makuch RW Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778 [TBL] [Abstract][Full Text] [Related]
4. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789 [TBL] [Abstract][Full Text] [Related]
6. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada. Rahme E; Toubouti Y; Hunsche E Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440 [TBL] [Abstract][Full Text] [Related]
7. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. Wolfe F; Michaud K; Burke TA; Zhao SZ J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808 [TBL] [Abstract][Full Text] [Related]
8. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines. Moride Y; Ducruet T; Boivin JF; Lavoie F; Rochon S Can J Clin Pharmacol; 2005; 12(2):e201-11. PubMed ID: 15998959 [TBL] [Abstract][Full Text] [Related]
9. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567 [TBL] [Abstract][Full Text] [Related]
10. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336 [TBL] [Abstract][Full Text] [Related]
11. Factors associated with celecoxib and rofecoxib utilization. Rawson NS; Nourjah P; Grosser SC; Graham DJ Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796 [TBL] [Abstract][Full Text] [Related]
12. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791 [TBL] [Abstract][Full Text] [Related]
13. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Sun SX; Lee KY; Bertram CT; Goldstein JL Curr Med Res Opin; 2007 Aug; 23(8):1859-66. PubMed ID: 17605893 [TBL] [Abstract][Full Text] [Related]
14. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790 [TBL] [Abstract][Full Text] [Related]
15. Persistence with COX-2 inhibitors in managed care: an analysis of claims data. Harley C; Wagner S Manag Care Interface; 2003 Oct; 16(10):38-45. PubMed ID: 14606259 [TBL] [Abstract][Full Text] [Related]
16. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs. Spalding WM; Reeves MJ; Whelton A Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969 [TBL] [Abstract][Full Text] [Related]
17. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Dai C; Stafford RS; Alexander GC Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363 [TBL] [Abstract][Full Text] [Related]
18. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rahme E; Nedjar H Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138 [TBL] [Abstract][Full Text] [Related]
19. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Stephens J; Laskin B; Pashos C; Peña B; Wong J Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii40-52. PubMed ID: 14585917 [TBL] [Abstract][Full Text] [Related]
20. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Depont F; Fourrier A; Merlière Y; Droz C; Amouretti M; Bégaud B; Bénichou J; Moride Y; Velo GP; Sturkenboom M; Blin P; Moore N; Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):891-900. PubMed ID: 17351983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]